Ennaid Therapeutics Announces Development of ENU200, A New Antiviral Therapeutic for the Treatment of COVID-19

Ennaid Therapeutics, LLC, a specialty pharmaceutical company that uses its artificial intelligence (AI)-based drug discovery platforms to develop antiviral drugs, today announced that it is advancing the development of ENU200, as a therapeutic to treat the up to 80% of asymptomatic, mild to moderate cases of COVID-19 viral infections.

Read More